| Date | Title | Description |
| 21.05.2026 | Cagent Vascular Inks $41M Series D Round |
WAYNE, PA, Cagent Vascular has announced the closing of a $41 million Series D financing round.
>> Click here for more funding data on Cagent Vascular
>> To export Cagent Vascular funding data to PDF and Excel, click here
Cagen... |
| 20.05.2026 | Cagent Vascular raises $41m for dual-modality IVL platform advancement | - |
| 19.05.2026 | Cagent Vascular: $41 Million Series D Raised Following First Human Use Of Serranator SONIC IVL System | Cagent Vascular announced the successful completion of first human-use cases with the Serranator SONIC Intravascular Lithotripsy (IVL) System and the closing of an oversubscribed $41 million Series D financing round.
The financing will supp... |
| 20.02.2025 | Cagent Vascular Receives $15M in Growth Capital From Trinity Capital | Cagent Vascular, a Wayne, PA-based developer of serration technology for vessel dilation in endovascular interventions, received $15M in growth capital from Trinity Capital (NASDAQ: TRIN).
This capital augmented $45M of equity financing led... |
| 08.05.2024 |
Cagent Vascular names former Carl Zeiss Meditech exec as CEO | [Image courtesy of LinkedIn]Cagent Vascular announced this week that it has appointed Brian Walsh as CEO, effective immediately.
Walsh has been chairing the company’s board of directors since March 2018 and will continue as chair. He will s... |
| 22.02.2024 | Cagent Vascular Raises $30 Million Series C Financing | Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M. U.S. Venture Partners (USVP), led the round. Participation included new investor Blue Ridge Medi... |
| 21.02.2024 | Cagent Vascular Raises $30M in Series C Financing | Cagent Vascular, a Wayne, PA-based commercial stage medical device company, raised $30M in Series C funding.
The round was led by Venture Partners, with participation from new investors Blue Ridge Medical, and existing investors including S... |
| 21.02.2024 | Cagent Vascular sharpens up with $30M for serrated balloon catheter | In much the same way that Cagent Vascular’s flagship device is designed to help open up blocked arteries to promote blood flow, a recent round of funding for the startup is now slated to widen the device’s path in the commercial market.
The... |
| 20.02.2024 | Cagent Vascular Raises $30 Million Series C Financing | - |
| 19.07.2023 | Cagent Vascular Announces Initial RECOIL Study Results: Serranator Demonstrates 49% Less Recoil Than POBA In BTK Arteries | This Core Lab-Adjudicated Recoil analysis, the first of its kind, evaluated vessel recoil in lesions treated with Serranator® verses Plain Old Balloon Angioplasty (POBA). The study results demonstrated that lesions treated using Serration A... |
| 25.05.2022 | At an estimated value of over USD 4.02 billion in 2021, the Global Peripheral Artery Disease Market is predicted to thrive at a CAGR of 7.5% and valued at over USD 7.80 billion over the forecast year ... | New York, May 25, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Peripheral Artery Disease Market by Type, Global Opportunity Analysis and Industry Forecast, 2022 – 2030" - https://www.reportlinker.... |
| 22.06.2021 | Cagent Vascular Receives $9M Investment to Accelerate Marketing of its Lead Product | Cagent Vascular received the investment from Sectoral Asset Management. Marc-Andre Marcotte, a partner and COO at the Canadian investment firm, has joined Cagent’s board of directors.
Founded in 2014, Cagent specializes in developing next g... |
| 23.04.2020 | Cagent Vascular Announces FDA 510(k) Clearance for its Serranator Device for the Infrapopliteal Indication and Completion of its PRELUDE-BTK Clinical Trial Enrollment | WAYNE, Pa.–(BUSINESS WIRE)–
The Serranator device is the first and only angioplasty balloon FDA Cleared and CE Marked that embeds serration technology into a semi-compliant balloon for treating Peripheral Artery Disease (PAD). It is designe... |
| 12.07.2018 | Cagent Vascular Raises $11.87M in Series B Funding | Cagent Vascular, a Wayne, Pa.-based developer of angioplasty balloons using proprietary serration technology, completed an $11.87m in Series B funding.
The round was led by two strategic investors including one that participated in the Seri... |
| 12.07.2018 | Cagent Vascular Raises $11.87M | WAYNE, Pa.--(BUSINESS WIRE)--Cagent Vascular®, a developer of next generation angioplasty balloons using proprietary serration technology, announced the completion of $11.87 million in Series B funding. The round was led by two strategic in... |
| 16.11.2017 | Ben Franklin Approved 4.4M in 25 Early Stage Companies | |
| 28.07.2017 | Twelve Health Companies Creating an Impact in our Region | When you talk about trends in tech there are two mentions that you cannot leave out: impact and health technology. Philadelphia has blossomed into a burgeoning hub for startups in health technology. With pillars in the industry like Siemens... |
| 05.06.2017 | Cagent Vascular Completes Enrollment of PRELUDE Study Using Serranator Device |
The purpose of this prospective, single-arm, multicenter feasibility study is to show the safety and efficacy of the Serranator® Alto device used in the Superficial Femoral Artery (SFA) and/or Popliteal Artery.
The PRELUDE study is led by ... |
| 18.08.2016 | Ben Franklin Approved $2.9M for 13 Early Stage Companies | |
| 31.08.2012 | As peripheral artery disease innovations move forward, endoscopy stapler system raises $11M | Carol Burns, the co-founder and CEO of the Wayne, Pennsylvania-based company, said its system produces “less foreign material in the artery, less long-term chronic injury to the vessel and the ability to perform ‘spot’ treatment to the vess... |
| 28.02.2012 | Peripheral artery disease device company raises $2.5 million | Angioplasty is a procedure that uses balloons to widen narrowed or obstructed blood vessels. In the case of peripheral artery disease, the blood vessels can be located in the abdomen, legs or kidneys. Peripheral artery disease affects 8 mil... |
| 22.02.2012 | Magnetic therapy for peripheral artery disease gets $7 million | The treatment involves magnetically guided nanoparticles that deliver drugs to diseased blood vessels for the treatment of peripheral artery disease. The initial product Vascular Magnetics is developing uses Paclitaxel, an antirestenosis dr... |
| 27.09.2010 | Peripheral artery disease drug developer TheraVasc raises $1.8M | Promoted
Telemedicine’s potential to provide healthcare to the world’s most vulnerable
Teladoc Health Head of R&D Yulun Wang highlights the impact of virtual care in underserved populations around the globe through the World Telehealth ... |
| - | Cagent Vascular | “Cagent Vascular Inc. is a developer of next generation angioplasty balloons using Serration Technology for the treatment of cardiovascular disease.” |
| - | As peripheral artery disease innovations move forward, endoscopy stapler system raises $11M | A medical device company with a combination catheter-stapler device to improve outcomes in balloon angioplasty procedures to treat peripheral artery disease has raised $11 million. The funding comes after the company secured CE Mark approva... |
| - | Peripheral artery disease device company raises $2.5 million | A medical device company developing an implant for optimized angioplasty to treat peripheral artery disease has raised $2.5 million since September.
The device is a permanent implant that would tack up the plaque blocking or restricting blo... |
| - | Magnetic therapy for peripheral artery disease gets $7 million | A therapeutics company that has developed a magnetic drug-delivery therapy to treat peripheral artery disease has received a $7 million venture capital investment in a series A financing round.
Devon Park Bioventures, a Wayne, Pennsylvania ... |
| - | Peripheral artery disease drug developer TheraVasc raises $1.8M | TheraVasc Inc., which is reformulating a drug to treat vascular diseases, has raised $1.8 million in its first round of investment capital.
The funding comes from existing investors JumpStart Inc. and Portal Capital, and new investors North... |
